Presentations

Pharmacology as a tool to dose individualize cancer therapy
Dr. M. Ratain
Early biomarkers as a tool to dose individualize cancer therapy
Dr. T. Yap
Obstacles to use dose optimization in an early stage of cancer drug development
Dr. R. Bruno
A survey of new oncology drug approvals in the United States from 2010 to 2013 – Development paradigms, exposure-response, and the elusiveness of the optimal dose
Dr. B. Lum
Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer
Dr. G. Bjarnason
Toxicity-adjusted dose (TAD) of sunitinib gives low intra-patient variation of trough levels: A longitudinal study in metastatic renal cell cancer (mRCC)
Dr. H. Gurney
Individualized pharmacokinetically-guided dosing of pazopanib: A feasibility study in cancer patients
Dr. S. Bins
The revenues of dose individualization in other disciplines: HIV therapy
Dr. C. Fletcher
Is cancer different? The first steps to dose individualize and optimize anticancer therapy
Dr. G. Demetri
Optimal TDM and pharmacodynamics of mitotane in adrenocortical cancer in children and adults
Dr. S. Ackland
Dose escalation of tamoxifen in patients with low endoxifen level: evidence for therapeutic drug monitoring - The TADE Study.
Dr. C. Lee
First intra-patient comparison of antidepressant use among tamoxifen patients
Dr. L. Binkhorst
Everolimus exposure strongly related to dose reductions and mucositis: results of a phase II study in patients with thyroid cancer
Dr. D. De Wit
Marker of bevacizumab efficacy: Which place for the pharmacokinetics?
Dr. BC. Serdjebi
Tyrosine Kinase Inhibitor (TKI) new oncology drug approvals in the United States from 2010 to 2013- A case of turning a blind eye to the optimal dose at the MTD?
Dr. B. Lum
Distinguishing safety response of a chemo–radium-223 combination using a model-based analysis of an individual cross-over design
Dr. A. Solms
Microdosing as a pharmacokinetic assessment tool to optimize dosing in children
Dr. W. Vaes
Dried blood spot sampling for therapeutic drug monitoring of pazopanib.
Dr. D. De Wit
Polymorphisms of nr1i2 and nr1i3 affect sorafenib and imatinib in vitro activity
Dr. L. Mbatchi
Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions
Dr. R. van Leeuwen
Preclinical modeling (PB/PK modeling) as a tool for dose optimization and estimate the clinical relevance of drug interactions
Dr. J. Gobburu
The use of PK/PD modeling early in drug development and for dose individualizing approaches
Dr. L. Friberg
PKPD modeling of individual lesion maximal standardized uptake value in gastrointestinal stromal tumor (GIST) patients treated with sunitinib
Dr. E. Schindler
Population PKPD modeling of abexinostat-induced thrombocytopenia in phase I and application for the determination of the dose/toxicity relationship
Dr. S. Fouliard
A pre-clinical PKPD framework for biomarker led decision making for prioritising dose and schedules for anti-cancer agents to test in the clinic
Dr. R. Jones
Mixed-effect modeling frameworks to optimize treatment of low-grade glioma patients, on population and individual levels
Dr. P. Mazzocco
Incorporation of dose individualizing approaches in the treatment of cancer – can we learn from the successes in ALL. How will this apply for solid tumors.
Dr. J. Schellens